Erythropoiesis-Stimulating Agents
Erythropoiesis-stimulating agents (ESAs) are prescription medications that stimulate red blood cell production by mimicking erythropoietin (EPO). FDA-approved for anemia in chronic kidney disease, chemotherapy-induced anemia, and surgical blood loss reduction. PRESCRIPTION ONLY - not supplements. NO GRADED OUTCOMES in this database but extensive clinical evidence supports efficacy for approved indications. SAFETY CONCERNS: Increased cardiovascular events, stroke, and tumor progression when targeting high hemoglobin levels. Black box warnings exist. Banned in sports (blood doping).
⚠️ Limited Research Available — This supplement has emerging preclinical research but no graded clinical outcomes yet. Evidence is based on animal or in-vitro studies only.
Quick Answer
What it is
Erythropoiesis-stimulating agents (ESAs) are prescription medications that stimulate red blood cell production by mimicking erythropoietin (EPO). FDA-approved for anemia in chronic kidney disease, chemotherapy-induced anemia, and surgical blood loss reduction.
Key findings
No graded findings are available yet.
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
ℹ️ Quick Facts: Erythropoiesis-Stimulating Agents
Quick Facts: Erythropoiesis-Stimulating Agents
- Best Evidence:No graded evidence
- Conditions Studied:0
- Research Outcomes:0